Dr. Mansuo Shannon joined AskBio in 2024 and serves as its Chief Scientific Officer (CSO). She is responsible for developing and implementing the company’s R&D strategy and leads all aspects of the discovery and development of AskBio’s gene therapy platform. Dr. Shannon also oversees the global teams charged with advancing that platform and provides scientific leadership to the CEO, Board of Directors, and company as a whole, in addition to being a key partner of the broader Bayer R&D leadership team and Bayer’s scientific community.

Prior to joining AskBio, Dr. Shannon served as CSO at Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, where she established a robust gene therapy product portfolio in neurology and rare diseases. Earlier in her career, she spent more than 10 years at Eli Lilly, where she served in leadership roles of increasing responsibility and advanced multiple therapeutics into human clinical trials for Alzheimer’s disease and Parkinson’s disease. Dr. Shannon also previously held scientific leadership roles at Chugai/Roche Group and Merck. 

Dr. Shannon earned her doctorate in Molecular Biology with Dr. Tom Shenk at Princeton University and conducted her postdoctoral research under Dr. Susumu Tonegawa (1987 Nobel Laureate) at the Massachusetts Institute of Technology.